This is a duplicate of my Dry Eye Digest blogspot blog - to see the full archives back to 2005, please click on that link.
Regenerx has reported positive results from their recent Phase II clinical trial. Sounds promising. Wish it were a larger cohort though.
RGN-259 Significantly Improves Signs and Symptoms of Severe Dry Eye in Phase 2 Clinical Trial
June 20, 2012
ROCKVILLE, Md.--(BUSINESS WIRE)--RegeneRx Biopharmaceuticals, Inc. (OTC Bulletin Board: RGRX) (“the Company” or “RegeneRx”) is reporting preliminary results from a double-masked, vehicle-controlled, physician-sponsored
Results expected in late October.
RegeneRx Announces Completion of Patient Treatment in RGN-259 Phase 2 Dry Eye Trial
ROCKVILLE, Md., Sep 23, 2011 (BUSINESS WIRE) -- RegeneRx Biopharmaceuticals, Inc. RGRX -3.13% ("the Company" or "RegeneRx") today announced that treatment and follow-up have been completed on 69 patients in the Company's Phase 2 clinical trial with RGN-259 for the treatment of dry eye syndrome, five more than the number of evaluable patients
Safety and Efficacy of Thymosin Beta 4 Ophthalmic Solution in Patients With Dry Eye (clinicaltrials.gov page)
RegeneRx Biopharmaceuticals reported enrolling all 72 patients in its phase 2 trial of its RGN-259 treatment for dry-eye syndrome.
Patients will receive RGN-259 or a placebo twice daily until Sept. 23. The Rockville biotech expects preliminary data available in October.
In animal models, RGN-259 worked better than Restasis
Between the good clinical results they're getting on RGN-259 and problems plaguing another unrelated drug they're working on, RGN-259 has been promoted to a real priority for this company which hopefully will translate to good news for US.
RegeneRx Focuses Immediate Clinical Development on Dry Eye Indication with RGN-259, Provides Update on AMI Phase 2 Study Clinical Hold
ROCKVILLE, Md.--(BUSINESS WIRE)--RegeneRx Biopharmaceuticals, Inc. (OTC Bulletin Board: RGRX) (“the
REG BIO : RegeneRx Reports New Statistically Significant Data Confirming Repair of Corneal Damage in Dry Eye Model
April 13, 2011
RegeneRx Biopharmaceuticals, Inc. (OTC Bulletin Board: RGRX) ("the Company" or "RegeneRx") today announced positive new data related to RGN-259, its preservative-free ophthalmic drug candidate. In a second "dry eye" study conducted by Ora, Inc. using their Preclinical CAE? Murine (mouse) Model, four active concentrations of